1. Home
  2. ATS vs VRDN Comparison

ATS vs VRDN Comparison

Compare ATS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATS Corporation

ATS

ATS Corporation

HOLD

Current Price

$26.62

Market Cap

2.5B

Sector

N/A

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$33.11

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATS
VRDN
Founded
1978
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.7B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
ATS
VRDN
Price
$26.62
$33.11
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$39.73
AVG Volume (30 Days)
100.1K
1.6M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,930,283,080.00
$70,789,000.00
Revenue This Year
$17.12
$26,477.48
Revenue Next Year
$5.12
$6.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23340.07
52 Week Low
$20.90
$9.90
52 Week High
$32.73
$33.34

Technical Indicators

Market Signals
Indicator
ATS
VRDN
Relative Strength Index (RSI) 51.97 67.37
Support Level $26.89 $32.29
Resistance Level $28.11 $33.29
Average True Range (ATR) 0.68 1.19
MACD 0.22 -0.15
Stochastic Oscillator 60.91 77.75

Price Performance

Historical Comparison
ATS
VRDN

About ATS ATS Corporation

ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: